Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
ARC Centre for Cryo-electron Microscopy of Membrane Proteins, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
Biochemistry. 2024 May 7;63(9):1089-1096. doi: 10.1021/acs.biochem.4c00114. Epub 2024 Apr 11.
Inhibition of calcitonin gene-related peptide (CGRP) or its cognate CGRP receptor (CGRPR) has arisen as a major breakthrough in the treatment of migraine. However, a second CGRP-responsive receptor exists, the amylin (Amy) 1 receptor (AMYR), yet its involvement in the pathology of migraine is poorly understood. AMYR and CGRPR are heterodimers consisting of receptor activity-modifying protein 1 (RAMP1) with the calcitonin receptor (CTR) and the calcitonin receptor-like receptor (CLR), respectively. Here, we present the structure of AMYR in complex with CGRP and Gs protein and compare it with the reported structures of the AMYR complex with rat amylin (rAmy) and the CGRPR in complex with CGRP. Despite similar protein backbones observed within the receptors and the N- and C-termini of the two peptides bound to the AMYR complexes, they have distinct organization in the peptide midregions (the bypass motif) that is correlated with differences in the dynamics of the respective receptor extracellular domains. Moreover, divergent conformations of extracellular loop (ECL) 3, intracellular loop (ICL) 2, and ICL3 within the CTR and CLR protomers are evident when comparing the CGRP bound to the CGRPR and AMYR, which influences the binding mode of CGRP. However, the conserved interactions made by the C-terminus of CGRP to the CGRPR and AMYR are likely to account for cross-reactivity of nonpeptide CGRPR antagonists observed at AMYR, which also extends to other clinically used CGRPR blockers, including antibodies.
降钙素基因相关肽(CGRP)或其同源 CGRP 受体(CGRPR)的抑制作用已成为治疗偏头痛的重大突破。然而,还存在第二种 CGRP 反应性受体,即胰岛淀粉样多肽(Amy)1 受体(AMYR),但其在偏头痛发病机制中的作用仍知之甚少。AMYR 和 CGRPR 是由受体活性修饰蛋白 1(RAMP1)与降钙素受体(CTR)和降钙素受体样受体(CLR)分别组成的异二聚体。在这里,我们展示了 AMYR 与 CGRP 和 Gs 蛋白复合物的结构,并将其与报道的 AMYR 与大鼠胰岛淀粉样多肽(rAmy)复合物和 CGRPR 与 CGRP 复合物的结构进行了比较。尽管在受体和结合到 AMYR 复合物的两种肽的 N-和 C-末端观察到类似的蛋白质骨架,但它们在肽中区域(旁路基序)具有独特的组织,这与各自受体细胞外结构域的动力学差异相关。此外,当比较与 CGRPR 和 AMYR 结合的 CGRP 时,CTR 和 CLR 原聚体的细胞外环(ECL)3、细胞内环(ICL)2 和 ICL3 的构象明显不同,这会影响 CGRP 的结合模式。然而,CGRP 的 C 末端与 CGRPR 和 AMYR 形成的保守相互作用可能解释了在 AMYR 观察到的非肽 CGRPR 拮抗剂的交叉反应性,这也扩展到其他临床使用的 CGRPR 阻断剂,包括抗体。